In vitro activities of fluconazole and voriconazole against clinical isolates of candida spp. determined by disk diffusion testing in Turin, Italy

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 4, 2009, Pages 1657-1659

  Mandras, Narcisa ^a   Tullio, Vivian ^a   Allizond, Valeria ^a   Scalas, Daniela ^a   Banche, Giuliana ^a   Roana, Janira ^a   Robbiano, Francesca ^b   Fucale, Giacomo ^c   Malabaila, Aurelio ^d   Maria Cuffini, Anna ^a   Carlone, Nicola ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c CTO HOSPITAL   (Italy)

^d OSPEDALE DEGLI INFERMI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; FLUCONAZOLE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KEFYR; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA SAKE; CANDIDA TROPICALIS; DISK DIFFUSION; DRUG MECHANISM; FUNGAL STRAIN; FUNGUS ISOLATION; IN VITRO STUDY; ITALY; LABORATORY TEST; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA; DIFFUSION; FLUCONAZOLE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

EID: 65649142613     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00998-08     Document Type: Article

References (19)

1. Borg-von Zepelin, M., L. Kunz, R. Riichel, U. Reichard, M. Weig, and U. Gross. 2007. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. J. Antimicrob. Chemother. 60:424-428.
2. Clinical and Laboratory Standards Institute. 2007. Zone diameter interpre-tive standards, corresponding minimal inhibitoiy concentration (MIC) inter-pretive breakpoints, and quality control limits for antifungal disk diffusion susceptibility testing of yeasts; 17th informational supplement. CLSI M44-S2. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Guaico, L., E. A. Debbia, R. Bandettini, L. Pescetto, A. Cavallero, M. C. Ossi, A. M. Schito, and A. Márchese. 2007. Antifungal resistance in Candida spp. isolated in Italy between 2002 and 2005 from children and adults. Int. J. Antimicrob. Agents 29:179-184. (Pubitemid 46073675)
4. Guinea, J., M. Sánchez-Somolinos, O. Cuevas, T. Peláez, and E. Bouza. 2006. Fluconazole resistance mechanisms in Candida krusei: the contribution of efflux-pumps. Med. Mycol. 44:575-578. (Pubitemid 44377568)
5. Hazen, K. C, E. J. Baron, A. L. Colombo, C. Girmenia, A. Sanchez-Sousa, A. Del Palacio, C. deBedout, D. L. Gibbs, and the Global Antifungal Sur-veillance Group. 2003. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffu-sion. J. Clin. Microbiol. 41:5623-5632.
6. Krcmery, V., and A. J. Barnes. 2002. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J. Hosp. Infect. 50:243-260. (Pubitemid 37554852)
7. Meis, J., M. Petrou, J. Bille, D. Ellis, D. Gibbs, and the Global Antifungal Surveillance Group. 2000. A global evaluation of the susceptibility of Can-dida species to fluconazole by disk diffusion. Diagn. Microbiol. Infect. Dis. 36:215-223. (Pubitemid 30197110)
8. National Committee for Clinical Laboratory Standards. 2004. Method for antifungal disk diffusion susceptibility testing of yeasts. Approved standard M44-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
9. Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Larsen, H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kaufman, J. Cleary, J. E. Mangino, and J. Lee. 2003. Antifungal susceptibility survey of 2000 blood-stream Candida isolates in the United States. Antimicrob. Agents Che-mother. 47:3149-3154. (Pubitemid 37229571)
10. Panackal, A. A., J. L. Gribskov, J. F. Staab, K. A. Kirby, M. Rinaldi, and K. A. Marr. 2006. Clinical significance of azole antifungal drug cross-resis-tance in Candida glabrata. J. Clin. Microbiol. 44:1740-1743. (Pubitemid 43726263)
11. Pappas, P. G., J. H. Rex, J. D. Sobel, S. G. Filler, W. E. Dismukes, T. J. Walsh, and J. Edwards. 2004. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38:161-189. (Pubitemid 38113025)
12. Pfaller, M. A., D. J. Diekema, M. G. Rinaldi, R. Barnes, B. Hu, A. V. Veselov, N. Tiraboschi, E. Nagy, D. L. Gibbs, and the Global Antifungal Surveillance Group. 2005. Results from the ARTEMIS DISK Global Antifungal Surveil-lance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion test-ing. J. Clin. Microbiol. 43:5848-5859. (Pubitemid 43100628)
13. Pfaller, M. A., D. J. Diekema, D. L. Gibbs, V. A. Newell, J. F. Meis, I. M. Gould, W. Fu, A. L. Colombo, E. Rodriguez-Noriega, and the Global Anti-fungal Surveillance Study. 2007. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of suscep-tibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 45:1735-1745. (Pubitemid 46933900)
14. Pfaller, M. A, D. J. Diekema, S. A. Messer, L. Boyken, and R. J. Hollis. 2003. Activities of fluconazole and voriconazole against 1,586 recent clinical iso-lates of Candida species determined by broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Suscep-tibility Program, 2001. J. Clin. Microbiol. 41:1440-1446. (Pubitemid 36428086)
15. Reuter, C. W., M. A. Morgan, F. C. Bange, F. Gunzer, M. Eder, B. Herten-stein, and A. Ganser. 2005. Candida kefyr as an emerging pathogen causing nosocomial bloodstream infections in neutropenic leukemia patients. Clin. Infect. Dis. 41:1365-1366. (Pubitemid 41532689)
16. Rogers, T. 2006. Antifungal drug resistance: limited data, dramatic impact? Int. J. Antimicrob. Agents 27(Suppl. I)i7-11.
17. Sugita, T., K. Takeo, M. Ohkusu, E. Virtudazo, M. Takashima, E. Asako, F. Ohshima, S. Harada, C. Yanaka, A. Nishikawa, L. Majoras, and M. Sipiczki. 2004. Fluconazole-resistant pathogens Candida inconspicua and C. norveg-ensis: DNA sequence diversity of the rRNA intergenic spacer region, anti-fungal drag susceptibility, and extracellular enzyme production. Microbiol. Immunol. 48:761-766. (Pubitemid 39421418)
18. Swinne, D., M. Watelle, and N. Nolard. 2005. In vitro activities of voricon-azole, fluconazole, itraconazole and amphotericin B against non-Candida albicans yeast isolates. Rev. Iberoam. Micol. 22:24-28. (Pubitemid 40675571)
19. Testore, G. P., L. Dori, A. R. Buonuomini., G. C. Schito, O. Soro, G. Fortina, S. Androni, N. Carlone, V. Tulilo, and M. Andreoni. 2004. In vitro flucon-azole susceptibility of 1565 clinical isolates of Candida species evaluated by the disk diffusion method performed using NCCLS M44-A guidelines. Diagn. Microbiol. Infect. Dis. 50:187-192. (Pubitemid 39487292)